Merck Sharp + Dohme Corp.

Elexopharm Gmbh

Lina Yin

Amjad Ali

Rolf Wolfgang Hartmann

Michael Man-Chu Lo

Ralf Heim

Qingzhong Hu

Edward Metzger

Christina Zimmer

Emmanuel Bey

Yusheng Xiong

Timothy J Henderson

Bheemashankar A Kulkarni

Clare London

Scott B Hoyt

Jerry Andrew Taylor

Swapan Kumar Samanta

Rohit Saxena

Whitney Lane Petrilli

Quingzhong Hu

Michael Lo

Rolf Hartmann

Bey; Emmanuel

Qungzhong Hu

This invention relates to indoline compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variables are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.

Indoline compounds as aldosterone synthase inhibitors

This invention relates to indo line compounds of the structural formula I, or their pharmaceutically acceptable salts, wherein the variables are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase. 

This invention relates to tricyclic triazole compounds or their pharmaceutically acceptable salts. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the above-cited compounds or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase. 

Aldosterone synthase inhibitors

This invention relates to tricyclic triazole analogs of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase. 

Growing community of inventors

Saarbrucken, Germany

Lina Yin